Successful use of cannabidiol in nonconvulsive status epilepticus in Angelman syndrome
- PMID: 39175208
- PMCID: PMC11450666
- DOI: 10.1002/epi4.12948
Successful use of cannabidiol in nonconvulsive status epilepticus in Angelman syndrome
Conflict of interest statement
PN has received speaker fees or fundings or has participated in advisory boards for Angelini and UCB. DPL, AM, CT report no conflict of interest. VF has received speaker fees or fundings or has participated in advisory boards for Zogenix, Neuraxpharm, Angelini, Eisai, and Neuraxpharm. SN has served on scientific advisory boards for GW Pharma, BioMarin, Arvelle, Marinus, and Takeda; has received speaker honoraria from Eisai, Biomarin, Livanova, Sanofi; has served as an investigator for Zogenix, Marinus, Biomarin, UCB, Roche.
Figures

References
-
- European Medicines Agency . Epidyolex [Internet]. Human medicine European public assessment report (EPAR) last updated on 04/07/2023 [cited 2023 Oct 10]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources